Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer
Open Access
- 8 July 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (18), 5131-5140
- https://doi.org/10.1158/1078-0432.ccr-21-0921
Abstract
Purpose:. Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood. We examined the genetics of thyroid immune-related adverse events (irAE).Experimental Design:. In patients with non–small cell lung cancer (NSCLC) treated with CPIs at Memorial Sloan Kettering (MSK) and Vanderbilt University Medical Center (VUMC), we evaluated thyroid irAEs. We typed germline DNA using genome-wide single-nucleotide polymorphism (SNP) arrays and imputed genotypes. Germline SNP imputation was also performed in an independent Dana-Farber Cancer Institute (DFCI) cohort. We developed and validated polygenic risk scores (PRS) for hypothyroidism in noncancer patients using the UK and VUMC BioVU biobanks. These PRSs were applied to thyroid irAEs and CPI response in patients with NSCLC at MSK, VUMC, and DFCI.Results:. Among 744 patients at MSK and VUMC, thyroid irAEs occurred in 13% and were associated with improved outcomes [progression-free survival adjusted HR (PFS aHR) = 0.68; 95% confidence interval (CI), 0.52–0.88]. The PRS for hypothyroidism developed from UK Biobank predicted hypothyroidism in the BioVU dataset in noncancer patients [OR per standard deviation (SD) = 1.33, 95% CI, 1.29–1.37; AUROC = 0.6]. The same PRS also predicted development of thyroid irAEs in both independent cohorts of patients treated with CPIs (HR per SD = 1.34; 95% CI, 1.08–1.66; AUROC = 0.6). The results were similar in the DFCI cohort. However, PRS for hypothyroidism did not predict CPI benefit.Conclusions:. Thyroid irAEs were associated with response to anti–PD-1 therapy. Genetic risk for hypothyroidism was associated with risk of developing thyroid irAEs. Additional studies are needed to determine whether other irAEs also have shared genetic risk with known autoimmune disorders and the association with treatment response.Keywords
Other Versions
Funding Information
- National Institutes of Health (R01-CA227466, K24-CA169004, T32-CA009207, K30-UL1TR00457, T32-GM007347, F30-HL140756, U54CA217450–01, U01CA224276–01, P30-CA086485, UG1CA233259, U01CA253560–01, R01-CA227237, R01-CA244569, P30-CA008748, UL1TR002243, 1–19-PDF-131, CI-98–18)
This publication has 53 references indexed in Scilit:
- A CRISPR/Cas9 toolkit for multiplex genome editing in plantsBMC Plant Biology, 2014
- Genetic Variants Regulating Immune Cell Levels in Health and DiseaseCell, 2013
- Thyroid Dysfunction from Antineoplastic AgentsJNCI Journal of the National Cancer Institute, 2011
- Genetic Susceptibility to Autoimmune Thyroid Disease: Past, Present, and FutureThyroid®, 2010
- Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk lociNature Genetics, 2010
- Genetics of Type 1A DiabetesThe New England Journal of Medicine, 2009
- Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized MedicineClinical Pharmacology & Therapeutics, 2008
- Heritability of serum TSH, free T4 and free T3 concentrations: a study of a large UK twin cohortClinical Endocrinology, 2007
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesAmerican Journal of Human Genetics, 2007
- Major Genetic Influence on the Regulation of the Pituitary-Thyroid Axis: A Study of Healthy Danish TwinsJournal of Clinical Endocrinology & Metabolism, 2004